192 related articles for article (PubMed ID: 12678518)
1. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
2. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
3. Male breast cancer in the veterans affairs population: a comparative analysis.
Nahleh ZA; Srikantiah R; Safa M; Jazieh AR; Muhleman A; Komrokji R
Cancer; 2007 Apr; 109(8):1471-7. PubMed ID: 17342768
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia.
Serra Díaz C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Baltasar A; Medrano J
Br J Surg; 1999 Sep; 86(9):1190-7. PubMed ID: 10504376
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic significance of apolipoprotein D in breast cancer.
Díez-Itza I; Vizoso F; Merino AM; Sánchez LM; Tolivia J; Fernández J; Ruibal A; López-Otín C
Am J Pathol; 1994 Feb; 144(2):310-20. PubMed ID: 8311115
[TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor expression in gynaecomastia and male breast carcinoma.
Ferreira M; Mesquita M; Quaresma M; André S
Histopathology; 2008 Jul; 53(1):56-61. PubMed ID: 18613925
[TBL] [Abstract][Full Text] [Related]
7. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
8. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
[TBL] [Abstract][Full Text] [Related]
10. Oncogenes in male breast cancer.
Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
[TBL] [Abstract][Full Text] [Related]
11. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
12. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein D expression in metastasic lymph nodes of breast cancer.
Lamelas ML; Vázquez J; Enguita MI; Rodríguez JC; González LO; Merino AM; Vizoso F
Int J Surg Investig; 2000; 2(4):285-93. PubMed ID: 12678530
[TBL] [Abstract][Full Text] [Related]
15. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
16. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
17. REG1A expression is an independent factor predictive of poor prognosis in patients with breast cancer.
Sasaki Y; Minamiya Y; Takahashi N; Nakagawa T; Katayose Y; Ito A; Saito H; Motoyama S; Ogawa J
Ann Surg Oncol; 2008 Nov; 15(11):3244-51. PubMed ID: 18781363
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of cyclin D1 in breast cancer.
Bilalović N; Vranić S; Basić H; Tatarević A; Selak I
Croat Med J; 2005 Jun; 46(3):382-8. PubMed ID: 15861516
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
20. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
